Akebia Therapeutics Files Routine 8-K on Operations & Financial Condition

Ticker: AKBA · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1517022

Akebia Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAkebia Therapeutics, Inc. (AKBA)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.00001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, disclosure, financial-condition, operations

TL;DR

**Akebia Therapeutics filed a routine 8-K, no major news, just standard disclosure.**

AI Summary

Akebia Therapeutics, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD disclosure. This filing is a routine update, indicating the company is providing current financial information to the public and satisfying its disclosure obligations. For investors, this matters because it signals transparency and adherence to regulatory requirements, which can build confidence, although the filing itself doesn't contain specific new financial figures or events that would drastically alter the stock's immediate outlook.

Why It Matters

This filing is a standard regulatory update, ensuring Akebia Therapeutics, Inc. remains transparent with its financial condition and operations, which is crucial for investor confidence.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing for disclosure, not announcing any specific event that would inherently increase or decrease risk.

Analyst Insight

Given this is a routine disclosure without specific new financial details or events, a smart investor would note the filing for compliance but await more substantive financial reports (like 10-K or 10-Q) for actionable insights into Akebia Therapeutics, Inc.'s performance.

Key Numbers

  • 0001517022-24-000004 — Accession Number (Unique identifier for this specific SEC filing.)
  • 20240108 — Filing Date (The date this 8-K was filed with the SEC.)
  • 36 — Public Document Count (Number of documents associated with this filing.)
  • 001-36352 — SEC File Number (The Commission File Number for Akebia Therapeutics, Inc.)
  • 20-8756903 — IRS Employer Identification No. (The IRS Employer Identification Number for Akebia Therapeutics, Inc.)

Key Players & Entities

  • Akebia Therapeutics, Inc. (company) — the registrant filing the 8-K
  • January 8, 2024 (date) — date of earliest event reported and filing date
  • Delaware (company) — state of incorporation for Akebia Therapeutics, Inc.
  • 001-36352 (dollar_amount) — Commission File Number
  • 20-8756903 (dollar_amount) — IRS Employer Identification No.
  • 245 First Street, Cambridge, Massachusetts, 02142 (company) — address of principal executive offices for Akebia Therapeutics, Inc.
  • 617-871-2098 (dollar_amount) — registrant's telephone number
  • AKBA (company) — trading symbol for Akebia Therapeutics, Inc. Common Stock
  • The Nasdaq Capital Market (company) — exchange where Akebia Therapeutics, Inc. Common Stock is registered

FAQ

What is the purpose of this 8-K filing by Akebia Therapeutics, Inc.?

This 8-K filing by Akebia Therapeutics, Inc. is to report on 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' as of January 8, 2024, indicating a routine update on their financial status and compliance with fair disclosure regulations.

What is the earliest event reported date for this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 8, 2024.

Where are Akebia Therapeutics, Inc.'s principal executive offices located?

Akebia Therapeutics, Inc.'s principal executive offices are located at 245 First Street, Cambridge, Massachusetts, 02142.

What is the trading symbol and the exchange where Akebia Therapeutics, Inc.'s Common Stock is registered?

The trading symbol for Akebia Therapeutics, Inc.'s Common Stock is AKBA, and it is registered on The Nasdaq Capital Market.

Does this 8-K filing indicate that Akebia Therapeutics, Inc. is an emerging growth company?

The filing includes a checkbox to indicate whether the registrant is an emerging growth company, but it is not checked (indicated by '☐'), suggesting Akebia Therapeutics, Inc. does not identify as an emerging growth company under Rule 405 of the Securities Act or Rule 12b-2 of the Exchange Act.

Filing Stats: 753 words · 3 min read · ~3 pages · Grade level 10.4 · Accepted 2024-01-08 08:02:35

Key Financial Figures

  • $0.00001 — ich registered Common Stock, par value $0.00001 per share AKBA The Nasdaq Capital Marke

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. John P. Butler, President and Chief Executive Officer of Akebia Therapeutics, Inc. (the "Company"), plans to present the information in the presentation attached hereto as Exhibit 99.1 (the "Presentation") at the 42 nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 at 11:15 a.m. PST, which includes preliminary unaudited net product revenue for Auryxia cumulative and for the fiscal year ended December 31, 2023. Spokespersons of the Company also plan to present the information in the Presentation at various meetings beginning on January 8, 2024, including investor and analyst meetings that coincide with the J.P. Morgan Healthcare Conference.

01

Item 7.01 Regulation FD Disclosure. The disclosure contained in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference. A copy of the Presentation is attached as Exhibit 99.1 to this Current Report onForm8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Items 2.02 and 7.01, including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, except as expressly set forth by specific reference in such a filing. By providing the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, the Company is not making an admission as to the materiality of any information herein. The information contained in this Current Report on Form 8-K is intended to be considered in the context of more complete information included in the Company's filings with the SEC and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Description 99.1 Akebia Therapeutics, Inc. Presentation January 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AKEBIA THERAPEUTICS, INC. Date: January 8, 2024 By: /s/ John P. Butler Name: John P. Butler Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.